Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
35.26
+1.17 (3.43%)
At close: Jun 26, 2026, 4:00 PM EDT
34.00
-1.26 (-3.57%)
After-hours: Jun 26, 2026, 4:37 PM EDT
Celldex Therapeutics Employees
Celldex Therapeutics had 198 employees as of December 31, 2025. The number of employees increased by 12 or 6.45% compared to the previous year.
Employees
198
Change (1Y)
12
Growth (1Y)
6.45%
Revenue / Employee
$4,369
Profits / Employee
-$1,432,556
Market Cap
2.77B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Ultragenyx Pharmaceutical | 1,371 |
| Vericel | 398 |
| Tarsus Pharmaceuticals | 370 |
| Vera Therapeutics | 339 |
| Nurix Therapeutics | 317 |
| Biohaven | 274 |
| Disc Medicine | 154 |
| Pharvaris | 134 |
CLDX News
- 2 days ago - Celldex Therapeutics Transcript: AGM 2026 - Transcripts
- 13 days ago - Celldex presents long-term results from Phase 2 study of barzolvolimab - TheFly
- 13 days ago - Celldex presents first-in-human results for CDX-622 - TheFly
- 13 days ago - Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting - GlobeNewsWire
- 13 days ago - Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting - GlobeNewsWire
- 17 days ago - Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress - GlobeNewsWire
- 17 days ago - Celldex price target raised to $45 from $38 at UBS - TheFly
- 4 weeks ago - Celldex Therapeutics Slides: Corporate presentation - Filings